MYGN vs NEOG
Myriad Genetics, Inc. and Neogen Corporation, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | MYGN | NEOG |
|---|---|---|
| Revenue | $824.5M | $894.7M |
| Net income | $-365.9M | $-1.1B |
| Gross margin | 69.9% | 47.1% |
| Net margin | −44.4% | −122.1% |
| Return on equity | −68.5% | −41.9% |
| Diluted EPS | −$3.95 | −$5.03 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-151.6M | $-46.4M |
| Equity | $368.0M | $2.1B |
| Net debt / equity | −0.08× | 0.37× |
| Current ratio | 2.49× | 3.32× |
| Revenue CAGR 5y | 8.2% | 16.4% |
| Profit CAGR 5y | — | — |
MYGN and NEOG book revenue within 15% of each other, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | MYGN | NEOG |
|---|---|---|
| FY2024 | $837.6M | $894.7M |
| FY2023 | $753.2M | $924.2M |
| FY2022 | $678.4M | $822.4M |
| FY2021 | $690.6M | $527.2M |
| FY2020 | $557.1M | $468.5M |
| FY2019 | $638.6M | $418.2M |
| FY2018 | $851.1M | $414.2M |
| FY2017 | $743.7M | $397.9M |
| FY2016 | $728.7M | $358.3M |
| FY2015 | $740.5M | $321.3M |
Net income by year
Bottom line
| Fiscal year | MYGN | NEOG |
|---|---|---|
| FY2024 | $-127.3M | $-1.1B |
| FY2023 | $-263.3M | $-9.4M |
| FY2022 | $-112.0M | $-22.9M |
| FY2021 | $-27.2M | $48.3M |
| FY2020 | $-223.6M | $60.9M |
| FY2019 | $-199.5M | $59.5M |
| FY2018 | $4.6M | $60.2M |
| FY2017 | $133.3M | $63.1M |
| FY2016 | $17.4M | $43.8M |
| FY2015 | $117.2M | $36.6M |
Advertisement
AdSense · Rectangle 336×280
More in this industry